Last Price
32.479
Today's Change
+0.01 (0.03%)
Day's Change
32.479 - 32.50
Trading Volume
7,955,821
Market Cap
3 Billion
Shares Outstanding
114 Million
Avg Volume
3,944,615
Avg Price (50 Days)
28.59
Avg Price (200 Days)
18.42
PE Ratio
-32.81
EPS
-0.99
Earnings Announcement
13-May-2024
Previous Close
32.47
Open
32.49
Day's Range
32.48 - 32.5
Year Range
7.261 - 32.5
Trading Volume
8,354,629
1 Day Change
0.00%
5 Day Change
0.00%
1 Month Change
0.03%
3 Month Change
32.57%
6 Month Change
138.65%
Ytd Change
36.99%
1 Year Change
215.95%
3 Year Change
678.90%
5 Year Change
169.54%
10 Year Change
364.00%
Max Change
260.89%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.